Gold prices steady ahead of Fed decision; weekly weakness noted
COPENHAGEN, DENMARK - Genmab (CSE:GMAB) A/S (NASDAQ:GMAB), a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer, has today disclosed details regarding its share buy-back program. The disclosure, made through a Form 6-K filing with the U.S. Securities and Exchange Commission, indicates that the company is actively engaging in transactions to repurchase its shares.
The announcement, dated Monday, provides specific information about the buy-back activities that took place during the week of June 9-13, 2025. Genmab has made this information public in accordance with the rules and regulations governing foreign private issuers in the United States.
According to the filing, the share buy-back program is part of a broader strategy previously outlined by the company. The report will be incorporated by reference into Genmab’s existing registration statements on Form S-8, which relate to the company’s employee share option programs.
The document filed does not specify the exact number of shares purchased or the prices paid, but it does include an appendix with detailed specifications for the transactions completed during the specified period. Investors and stakeholders can refer to the appendix for a complete breakdown of the buy-back transactions.
The buy-back program is executed under the authorization granted by the company’s board of directors and is conducted in accordance with the applicable regulatory requirements. This initiative is a common practice among publicly traded companies, allowing them to return value to shareholders and potentially impact the market price of their shares.
The filing was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer of Genmab, signifying the formal acknowledgment and authorization of the report by the company’s executive management.
This news comes as part of Genmab’s regular communication with its investors and the broader market, ensuring transparency in its financial operations. The company’s commitment to adhering to regulatory standards and providing timely information is evident in this latest filing with the SEC.
For further details, interested parties are encouraged to review the full text of the Form 6-K filing, which is publicly available through the SEC’s EDGAR database.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.